Celldex Therapeutics, Inc. (CLDX) vs Fortrea Holdings Inc. (FTRE)
A side-by-side comparison of Celldex Therapeutics, Inc. and Fortrea Holdings Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CLDX
Celldex Therapeutics, Inc.
$31.88HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
FTRE
Fortrea Holdings Inc.
$22.78HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — CLDX vs FTRE
growth of $100 · dividends reinvested · last 3yCLDX -8.4% (-2.9%/yr)FTRE -34.0% (-12.9%/yr)CLDX compounded faster over this window
CLDX FTRE
CLDX vs FTRE: by the numbers
- •FTRE is the larger company ($2.17B vs $2.12B market cap).
- •Both run net losses; FTRE's is the smaller (-3.18% vs -268385.71% net margin).
- •FTRE grew revenue faster over the past five years (1.09% vs -58.05% CAGR).
Metrics side by side
Valuation
| Metric | CLDX | FTRE |
|---|---|---|
| Forward P/E | N/A | 27.08 |
| P/S ratio | 18939.70 | 0.81 |
| P/B ratio | 2.97 | 4.13 |
| EV / EBITDA | N/A | 34.88 |
| FCF yield | N/A | 6.95% |
Profitability
| Metric | CLDX | FTRE |
|---|---|---|
| Gross margin | 100.00% | 17.11% |
| Operating margin | -19160.00% | 0.41% |
| Net margin | -268385.71% | -3.18% |
| ROE | -42.07% | -16.25% |
| ROIC | -45.19% | 0.62% |
Growth (annualized)
| Metric | CLDX | FTRE |
|---|---|---|
| Revenue CAGR (5Y) | -58.05% | 1.09% |
| FCF CAGR (5Y) | N/A | -12.98% |
| Total return CAGR (5Y) | -10.28% | N/A |
Frequently asked
- Which has grown faster, CLDX or FTRE?
- Over the past five years, FTRE grew revenue faster — CLDX at a -58.05% CAGR versus FTRE at 1.09%.
Go deeper
Dig into the metrics
Celldex Therapeutics ROEFortrea ROECelldex Therapeutics operating marginFortrea operating marginCelldex Therapeutics revenue growthFortrea revenue growthCelldex Therapeutics free cash flowFortrea free cash flow
Celldex Therapeutics & Fortrea appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.